Recall of Similasan Schlafstörungen Globuli Due to Quality Issues: Regulatory Implications for Swiss Market
As of February 11, 2026, Swissmedic announced a recall of Similasan Schlafstörungen Globuli due to quality issues affecting the product’s…
Switzerland updates on medical device regulation and quality.
156 articles
As of February 11, 2026, Swissmedic announced a recall of Similasan Schlafstörungen Globuli due to quality issues affecting the product’s…

The Jarisch-Herxheimer Reaction An adverse reaction to antibiotic treatment for spirochaetal infections, the Jarisch-Herxheimer reaction is a phenomenon clinicians should…

On February 11, 2026, Swissmedic announced the extension of the therapeutic indication for Fabhalta, a medical device used in various…

Swissmedic has issued a batch recall notice for Benocten Tropfen zum Einnehmen Lösung, a product used in healthcare settings. The…

Swissmedic, the Swiss Agency for Therapeutic Products, has announced the availability of the “Legacy devices” registration system. As of February…

A recent notification issued by Swissmedic, the Swiss Agency for Therapeutic Products, has brought attention to a critical issue regarding…

As of January 30, 2026, Swissmedic has updated its guidelines for the maintenance of medical devices, introducing Version 2.1 of…

As of 30 January 2026, Swissmedic has granted authorisation for Obgemsa, marking a significant milestone in the medical device landscape.…

Alyftrek Receives First Authorisation As of 30 January 2026, Alyftrek has been granted its first authorisation by Swissmedic, marking a…

Swissmedic, the Swiss Agency for Therapeutic Products, has conducted a focus campaign on importers of medical devices, resulting in significant…

The Swiss Agency for Therapeutic Products, Swissmedic, has announced a significant shift in the regulatory landscape for pharmaceuticals in Switzerland.…

PUBLISHED: January 29, 2026 Swissmedic has announced the approval of an extension of therapeutic indication for Nubeqa, a significant development…